Proposed Pharmacoeconomics Guideline p to Saudi Food & Drug ...

More documents

Recommendations

Info

5. RESULTS cont5.2 Results of variability analysis– Give the results for all subgroups analyzed.– Indicate the distribution impacts (i.e., benefits, harms,costs) and ICER results for any subgroups that arerelevant for equity purposes.5.3 Results of uncertainty analysis– State the results of sensitivity analysis.– Identify the greatest sources of uncertainty (i.e., keydrivers).
6. DISCUSSION6.1 Summary of results6.2 Study limitations6.3 Compare with other economic studies6.4 Generalizability6.5 Equity considerations6.6 Health services impact
Page 1 and 2: Proposed Pharmacoeconomics Guidelin
Page 3 and 4: Situations where economic evaluatio
Page 5 and 6: International Experiencee • Sever
Page 7 and 8: International ExperienceReimburseme
Page 9 and 10: Why do guidelines differ?• Some i
Page 11 and 12: Primary AudienceSaudi decision and
Page 13 and 14: Standard Reporting Format• A stru
Page 16 and 17: Executive Summary• The Executive
Page 18 and 19: 2. BACKGROUND• General comments o
Page 20 and 21: 4. METHODS4.1 Perspective- State an
Page 22 and 23: 4. METHODS cont.4.6 Outcome measure
Page 24 and 25: 4. METHODS cont.4.8 Modelling- Econ
Page 26 and 27: 4. METHODS cont.4.10 Time horizon-
Page 30 and 31: 7. CONCLUSIONS• Address the resea

Proposed Pharmacoeconomics Guideline p to Saudi Food & Drug ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?